New Medications for Substance Use Disorders: Challenges and Opportunities

Neuropsychopharmacology

Volumn 37, Issue 1, 2012, Pages 290-292

  Volkow, Nora D ^a   Skolnick, Phil ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; BUPRENORPHINE; DISULFIRAM; METHADONE; NALOXONE; NALTREXONE; NEUROTRANSMITTER RECEPTOR; NEUROTRANSMITTER TRANSPORTER; NICOTINE; NICOTINE VACCINE; VARENICLINE;

ADDICTION; ALCOHOL ABSTINENCE; ALCOHOLISM; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; COCAINE DEPENDENCE; DRUG ANTIGENICITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE TREATMENT; DRUG LEGISLATION; DRUG MARKETING; DRUG PROTEIN BINDING; HEALTH CARE SYSTEM; HUMAN; NERVE CELL PLASTICITY; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OPIATE ADDICTION; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; REWARD; SLOW DRUG RELEASE; SMOKING CESSATION; STIGMA; TOBACCO DEPENDENCE; TREATMENT OUTCOME; VACCINE PRODUCTION; WITHDRAWAL SYNDROME;

ANIMALS; DRUG DESIGN; FORECASTING; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PSYCHOPHARMACOLOGY; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84856102262     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.84     Document Type: Review

References (7)

1. Gastfriend DR (2011). Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci 1216: 144-166.
2. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA et al (2011). Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 89: 392-399.
3. NAS (1995). The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and the Private Sector. In: Fulco CE, Liverman CT, and Earley LE (eds). Board on Biobehavioral Health and Mental Disorders. National Academy Press: Washington, DC. pp 43-200.
4. ONDCP (2004). The Economic Costs of Drug Abuse in the United States. Executive Office of the President Office of National Drug Control Policy: Washington, DC http://www.ncjrs.gov/ondcppubs/publications/pdf/economic-costs. pdf.
5. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR (2008). Substance abuse vaccines. Ann N Y Acad Sci 1141: 257-269.
6. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR et al (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9: 203-214.
7. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F (2007). Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 64: 1575-1579. (Pubitemid 350106758)